Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
IPO Year:
Exchange: NYSE
Website: amneal.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | $9.00 → $12.00 | Neutral → Overweight | Analyst |
| 9/6/2024 | $9.00 | Underweight → Neutral | JP Morgan |
8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
SCHEDULE 13G - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
DEF 14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
144 - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
144 - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
10-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events. About AmnealAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 Brekiya autoinjector provides patie
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), an American biopharmaceutical company, and Apiject Systems, Corp. ("Apiject"), a medical technology company focused on advanced drug delivery, today announced a strategic collaboration to expand domestic production of Apiject's BFS-based injectable platform at Amneal's Brookhaven, NY facility. The collaboration will enable large-scale c
‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team's outstanding execution. We are very pleased with the commercial uptake of CREXONT® for Parkinson's Disease and the momentum of our recently launched injectable products, which are delivering tremendous value to pat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call
- Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients' Parkinson's Disease Sleep Scale-2 (PDSS-2) total and sub-scale scores - Treatment with CREXONT also resulted in significantly more patients waking up in an "On" state compared to immediate-release CD/LD patients, as part of separate study analysis - Sleep disturbances affect up to 80% of patients with Parkinson's disease1, highlighting the importance of extending treatment benefits beyond daytime symptoms Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed th
CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health Increases insurance coverage to over 50% of covered lives CREXONT was approved by the U.S. FDA to treat Parkinson's disease in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that three large insurance coverage accounts, the Veterans Administration (VA), UnitedHealthcare and CVS Health, have added CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease (PD) to their national prescription drug formularies. CREXONT is a prescription medication for the treatmen
- First ready-to-use, subcutaneous formulation of Bortezomib now available - Marks Amneal's fourth 505(b)(2) injectable product launch in the last year Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and Shilpa Medicare Limited ("Shilpa") today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Executive Officer and President, will participate in a fireside chat at 11:00 AM ET. A live webcast of the fireside chat will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event. About Amneal Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously
JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00
RBC Capital Mkts resumed coverage of Amneal Pharmaceuticals with a rating of Sector Perform and set a new price target of $5.00
The Goldman Sachs Group upgraded Amneal Pharmaceuticals from Sell to Buy and set a new price target of $6.50 from $4.00 previously
The Goldman Sachs Group upgraded Amneal Pharmaceuticals from Sell to Buy and set a new price target of $6.50 from $4.00 previously
Goldman upgraded Amneal Pharmaceuticals from Sell to Buy and set a new price target of $6.50 from $4.00 previously
Barclays reiterated coverage of Amneal Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $6.00 previously
‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team's outstanding execution. We are very pleased with the commercial uptake of CREXONT® for Parkinson's Disease and the momentum of our recently launched injectable products, which are delivering tremendous value to pat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call
‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒ ‒ Full Year 2024 Net Revenue of $2.79 billion; GAAP Net Loss of $117 million; Diluted Loss per Share of $0.38 ‒ ‒ Full Year 2024 Adjusted Net Income(1) of $187 million; Adjusted EBITDA(1) of $627 million; Adjusted Diluted EPS(1) of $0.58 ‒ ‒ Provides 2025 Financial Guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in Adjusted EBITDA(1)(2) – Amneal Pharmaceuticals,
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The acc
‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024. "Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we launched CREXONT® for the treatment of Parkinson's disease. Second, we announced our collaboration with Metsera, Inc. to leverage Amneal's exp
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced today that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call
‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT® U.S. FDA approval represents an exciting new long-term growth driver ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") announced its results today for the second quarter ended June 30, 2024. "Amneal achieved strong revenues and adjusted EBITDA in the second quarter, and we are pleased to raise full year 2024 guidance driven by broad-based growth across our business. Amneal is a diversified and growing global pharmaceuticals company built on o
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. To access the call through a conference line, dial 1
‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years ‒ ‒ Affirming 2024 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") announced its results today for the first quarter ended March 31, 2024. "We are extremely pleased with our outstanding start to the year, as Amneal generated record levels of revenues in the first quarter. For the first time, all three segments across our diversified business produced double-digit top-line g
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. To access the call through a conference line, dial 1 (83
SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13G - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif
- Celebrating Amneal's recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As entrepreneurs who founded Amneal in 2002, we are pleased to join the esteemed roster of Nasdaq-listed companies. Today Amneal is a growing global pharmaceutical leader with a diverse portfolio of essential medicines that help make healthy possible. Our focus on patient access and affordability allows us to improve countless lives, and our commitment to innovation a
Ms. Autor will further HIC's role as a sought-after advisor to global life sciences organizations Healthcare Innovation Catalysts, Inc. (HIC), a leading provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations, announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer. In this role, Ms. Autor will build on HIC's deep bench of cross-functional technical expertise, furthering the company's role as a sought-after advisor in both the private and public sectors. This press rele
- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. ("Amneal") (NYSE:AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol "AMRX". Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index. "We are pleased to join the community of global pharmaceutical companies listed on Nasdaq. We would also like to thank the NYSE for supporting the company over the last five years since our initial listing," sa
- Deepens leadership experience and capabilities to drive key growth areas of biosimilars, complex generics, injectables and specialty - Reem Malki joins as Senior Vice President, Chief Quality Officer, and Maryll W. Toufanian joins as Senior Vice President, Regulatory Strategy and Policy Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced it has appointed Reem Malki as Senior Vice President, Chief Quality Officer, and Maryll W. Toufanian as Senior Vice President, Regulatory Strategy and Policy. Ms. Malki brings over 30 years of quality operations and regulatory experience in the pharmaceuticals industry. She joins the Company from Alvotech, where she serv
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022. Mr. Pesquin joins the Company from Sanofi, a global pharmaceutical company, where he served leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America Head for General Medicines. Prior to that, Mr. Pesquin was the Global Head of the Diabetes and Cardiovascular franchise. He also previously served as the Global Head of Sanofi's Iberia and LATAM businesses. Before joining Sanofi, Mr. Pesquin held Regional Head, General Manager, S
- Adds new independent director with deep biopharmaceutical industry expertise in quality, regulatory and policy Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company") today announced that Deborah M. Autor has been appointed to the Company's Board of Directors, effective July 29, 2022. Chirag and Chintu Patel, Co-Chief Executive Officers, stated, "Deb brings decades of global public and private expertise in the biopharmaceutical sector to our board at an important time of growth for Amneal. She has a proven track record of service and impact throughout her distinguished career in quality, regulatory, and policy. We are delighted to welcome Deb to the board and look forward t
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and Fenel Eloi to serve on its Board of Directors, effective immediately. Mr. George brings more than two decades of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He served as the global division head and CEO of two $10 billion divisions of Novartis, Sandoz and Alcon, between 2008 and 2016, where in parallel he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharm
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“Amneal”), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs. “The acquisition of Kashiv Specialty aligns strongly with our Amneal 2.0 growth strategy which we expect will deliver substantial value for our Specialty and Generic